Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-11158

Furrer, D; Kaufmann, K; Tschuor, F; Reusch, C E; Lutz, T A (2010). The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats. Veterinary Journal, 183(3):355-357.

Accepted Version
[img] PDF - Registered users only


Glucagon-like peptide-1 (GLP-1) analogues and inhibitors of its degrading enzyme, dipeptidyl peptidase IV (DPPIV), are interesting therapy options in human diabetics because they increase insulin secretion and reduce postprandial glucagon secretion. Given the similar pathophysiology of human type 2 and feline diabetes mellitus, this study investigated whether the DPPIV inhibitor NVP-DPP728 reduces plasma glucagon levels in cats. Intravenous glucose tolerance tests (ivGTT; 0.5g/kg glucose after 12h fasting) and a meal response test (test meal of 50% of average daily food intake, offered after 24h fasting) were performed in healthy experimental cats. NVP-DPP728 (0.5-2.5mg/kg IV or SC) significantly reduced glucagon output in all tests and increased insulin output in the ivGTT. Follow-up studies will investigate the potential usefulness as therapy in diabetic cats.

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Institute of Veterinary Physiology
04 Faculty of Medicine > Center for Integrative Human Physiology
05 Vetsuisse Faculty > Veterinary Clinic > Department of Small Animals > Clinic for Small Animal Internal Medicine
DDC:570 Life sciences; biology
610 Medicine & health
630 Agriculture
Date:5 March 2010
Deposited On:13 Mar 2009 09:36
Last Modified:28 Nov 2013 01:17
Publisher DOI:10.1016/j.tvjl.2008.11.017
PubMed ID:19128990
Citations:Web of Science®. Times Cited: 4
Google Scholar™
Scopus®. Citation Count: 4

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page